Abstract
Schizophrenia has been claimed to be a “heterogeneous” disorder despite the fact that a diagnosis is made without reliable biomarkers but sorely with a constellation of “common” observable symptoms that however may be overlooked. Alternatively functional impairments are the prerequisite to make a diagnosis and may be simpler and more pragmatic to express objectively. It would then be reasonable to categorize patients according to the magnitude of psychosocial impairments, as has been done in terms of the severity of “classical” symptoms. In this context the author proposes a new paradigm in which patients with schizophrenia are classified into three functional subtypes using the anchors for the Clinical Global Impression Functioning subscale (CGI-F, adopted from the CGI) and the Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz): Class 1 patients are those with no to mild functional impairments (a score of 1–3 in the CGI-F and a score of 60–100 in the FACT-Sz), Class 2 patients are those with moderate to marked impairments (4 or 5 in the CGI-F and 40–59 in the FACT-Sz), and Class 3 patients are those with severe to most severe impairments (6 or 7 in the CGI-F 6,7 and 0–39 in the FACT-Sz). The author has no intention to ignore the importance of other domains of the illness but instead provides a simple framework as what the patient is actually doing is considered to represent the proximal “hard outcome” and certainly has the relevance in the management of schizophrenia. Implications of this pragmatic classification system for clinics and research are discussed.
Similar content being viewed by others
References
Lindenmayer JP, Grochowski S, Hyman RB. Five factor model of schizophrenia: replication across samples. Schizophr Res. 1995;14(3):229–34.
Suzuki T, Uchida H, Watanabe K, Kashima H. Treatment target in schizophrenia: a critical review and a clinical suggestion. Psychopharmacol Bull. 2008;41(4):80–102.
Suzuki T. Which rating scales are regarded as 'the standard' in clinical trials for schizophrenia? A critical review. Psychopharmacol Bull. 2011;44(1):18–31.
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–76.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
Suzuki T, Takeuchi H, Nakajima S, Nomura K, Uchida H, Yagi G, et al. Magnitude of rater differences in assessment scales for schizophrenia. J Clin Psychopharmacol. 2010;30(5):607–11. https://doi.org/10.1097/JCP.0b013e3181f0bae1.
Kumazaki T. What is a'mood-congruent' delusion? History and conceptual problems. Hist Psychiatry. 2011;22(87 Pt 3):315–31.
Suzuki T, Uchida H, Sakurai H, Ishizuki T, Tsunoda K, Takeuchi H, et al. Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. Psychiatry Res. 2015;227(2–3):265–9. https://doi.org/10.1016/j.psychres.2015.02.024.
Guy W. "Clinical Global Impressions". ECDEU Assessment Manual for Psychopharmacology—Revised. Rockville: U.S. Department of Health, Education, and Welfare; Public Health Service, Alcohol; Drug Abuse, and Mental Health Administration; National Institute of Mental Health; Psychopharmacology Research Branch; Division of Extramural Research Programs. 1976. p. 218–22.
Suzuki T, Uchida H, Nomura K, Takeuchi H, Nakajima S, Tanabe A, et al. Novel rating scales for schizophrenia - targeted inventory on problems in schizophrenia (TIP-Sz) and functional assessment for comprehensive treatment of schizophrenia (FACT-Sz). Schizophr Res. 2008;106(2–3):328–36. https://doi.org/10.1016/j.schres.2008.08.013.
Fenton WS, McGlashan TH. Natural history of schizophrenia subtypes. I. Longitudinal study of paranoid, hebephrenic, and undifferentiated schizophrenia. Arch Gen Psychiatry. 1991;48(11):969–77.
Ciompi L. Catamnestic long-term study on the course of life and aging of schizophrenics. Schizophr Bull. 1980;6(4):606–18.
Suzuki T, Uchida H, Takeuchi H, Tsuboi T, Hirano J, Mimura M. A review on schizophrenia and relapse--a quest for user-friendly psychopharmacotherapy. Hum Psychopharmacol. 2014;29(5):414–26.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, D.C.: American Psychiatric Association; 1994. p. 25–35.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Approval
This article does not contain any studies with human participants performed by any of the authors.
Conflict of Interest
Dr. Suzuki has received manuscript or speaker’s honoraria from Astellas, Dainippon Sumitomo, Eli Lilly, Elsevier Japan, Janssen, Meiji Seika, Novartis, Otsuka, and Weily Japan within the past three years.
Rights and permissions
About this article
Cite this article
Suzuki, T. Subtyping Schizophrenia by Social Functioning – a Pragmatic Proposal for Clinics and Research. Psychiatr Q 89, 533–538 (2018). https://doi.org/10.1007/s11126-017-9558-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11126-017-9558-z